Nitta Toshikatsu, Kataoka Jun, Ohta Masato, Fujii Kensuke, Tominaga Tomo, Inoue Yoshihiro, Kawasaki Hiroshi, Ishibashi Takashi
Division of Surgery Gastroenterological Center, Medico Shunju Shiroyama Hospital, Osaka, Japan.
Ann Med Surg (Lond). 2017 Jun 3;19:33-36. doi: 10.1016/j.amsu.2017.05.008. eCollection 2017 Jul.
We aimed to assess the efficacy of self-expanding metal stent (SEMS) implantation as palliative treatment for malignant colorectal obstruction.
We retrospectively reviewed the records of patients with malignant colorectal obstruction who underwent SEMS insertion as palliative treatment in our hospital between March 2013 and December 2016. We analyzed demographic, clinical, and operative characteristics.
A total of 13 patients (8 males, 5 females; median age, 80.1 years) were reviewed. Tumor location included the left colon, rectum, and right colon in 38.5%, 38.5%, and 23% of the patients, respectively. Advanced and early colorectal cancer were noted in 7 (63.6%) and 4 (36.4%) cases, respectively. The mean ColoRectal Obstruction Scoring System score was 0.92 before stenting and 3.92 after stenting. Oral intake was resumed at a median of 2.1 days after SEMS placement. Median stent patency was 7.6 months, and 69.2% of patients maintained stent patency until death or the end of follow-up. Stent-related adverse effects included: re-occlusion (4 cases, 30.8%); stent migration (1 case, 7.7%), and pain with tenesmus (2 cases, 15.4%). In patients with re-occlusion (median follow-up interval, 1.3 months), stent patency was maintained for a median of 10.3 months (early failure, within 3 months; late failure, >11 months).
SEMS placement as a palliative treatment is likely to fail within a year, leading to re-occlusion. It is very important to maintain vigilant monitoring using X-ray, CT, and colonoscopy after SEMS placement, with close cooperation between the endoscopist and surgeon. A logistic framework involving careful follow-up, even in the absence of symptoms, and a combined team involving endoscopists and surgeons should be established to support re-intervention and surgery. We recommend vigilant monitoring of patients who received SEMS placement for palliation of malignant colorectal obstruction.
我们旨在评估自膨式金属支架(SEMS)植入作为恶性结直肠梗阻姑息治疗的疗效。
我们回顾性分析了2013年3月至2016年12月期间在我院接受SEMS植入作为姑息治疗的恶性结直肠梗阻患者的记录。我们分析了人口统计学、临床和手术特征。
共纳入13例患者(8例男性,5例女性;中位年龄80.1岁)。肿瘤位置分别为左半结肠、直肠和右半结肠,占患者的38.5%、38.5%和23%。晚期和早期结直肠癌分别为7例(63.6%)和4例(36.4%)。结直肠梗阻评分系统的平均评分在支架置入前为0.92,置入后为3.92。SEMS置入后中位2.1天恢复经口进食。支架中位通畅时间为7.6个月,69.2%的患者直至死亡或随访结束时保持支架通畅。支架相关不良反应包括:再梗阻(4例,30.8%);支架移位(1例,7.7%),以及里急后重伴疼痛(2例,15.4%)。在再梗阻患者中(中位随访间隔1.3个月),支架通畅中位维持时间为10.3个月(早期失败,3个月内;晚期失败,>11个月)。
SEMS置入作为姑息治疗可能在一年内失败,导致再梗阻。SEMS置入后使用X线、CT和结肠镜进行密切监测非常重要,内镜医师和外科医生应密切合作。应建立一个后勤框架,包括即使无症状也进行仔细随访,以及一个由内镜医师和外科医生组成的联合团队,以支持再次干预和手术。我们建议对接受SEMS置入以缓解恶性结直肠梗阻的患者进行密切监测。